A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight but Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Study identifier:D7830C00001

ClinicalTrials.gov identifier:NCT04142424

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2693 Following Single Ascending Dose Administration in Male and Female Subjects of Non-childbearing Potential in Overweight but Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Medical condition

Metabolic disorders

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD2693, AZD2693, AZD2693, AZD2693, AZD2693, AZD2693, AZD2693, AZD2693, AZD2693, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo

Sex

All

Actual enrollment

73

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 28 Oct 2019
Primary Completion Date: 12 Nov 2021
Study Completion Date: 12 Nov 2021

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria